Selective serotonin reuptake inhibitor (SSRI) antidepressants taken by a woman during pregnancy do not impact her infant's growth over the first year, reports a new study from a Northwestern Medicine scientist.
There had been concern that antidepressant treatment during pregnancy reduced growth during the first year. Previous data suggested depression during pregnancy also could diminish infant growth.
But the new study showed infants born to mothers who took SSRIs during pregnancy had a similar weight, length and head circumference over the first year as infants born to non-depressed women who did not take antidepressants. The infants whose mothers took antidepressants were shorter at birth, but the difference disappeared by two weeks of age.
In addition, growth measurements for the infants of depressed women who did not take SSRIs were similar to the general population.
"Most women want to know about the effect of their depressive illness or the medication they take during pregnancy not only on the infant at birth, but also on the baby's longer-term growth and development," said Northwestern Medicine lead author Katherine L. Wisner, M.D. "This information may help women balance the risks and benefits of continuing their antidepressant treatment during pregnancy."
Wisner is director of Northwestern's Asher Center for the Study and Treatment of Depressive Disorders. She also is the Norman and Helen Asher Professor of Psychiatry and Behavioral Sciences and of obstetrics and gynecology at Northwestern University Feinberg School of Medicine and a physician at Northwestern Memorial Hospital.